Ryan Scott

Stage 1 polycythemia vera is manageable with monitoring, phlebotomy, medication and lifestyle changes, allowing patients to live healthy, normal lives.

The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.

Voranigo was safe and well tolerated in patients with grade 3 or 4 IDH-mutant gliomas, a type of brain cancer.

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Dr. Michael Staehler highlighted nutrition’s role in kidney cancer, noting that diet, stress management, and lifestyle can impact outcomes and well-being.

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with activating mutations.

Dr. Jorge E. Cortes discussed the evolution of chronic myeloid leukemia treatment and emerging strategies aimed at improving outcomes and quality of life.

Dr. Pamela L. Kunz sat down with CURE to discuss Neuroendocrine Tumors, or NETs, Awareness Month.

Dr. Adam J. Schoenfeld delivered an extensive overview of how cellular therapies are shaping the future of lung cancer care.

Dr. Catherine A. Shu highlights targeted therapies for patients with lung cancer, emphasizing advances, challenges and the importance of clinical trials.

Steve Brown and Lisa Booth explain how AI platforms like CureWise offer clarity, reduce anxiety, and support informed decisions during the cancer journey.

Patients with severe pancreatic cancer pain experienced consistent improvements in functionality and quality of life following targeted ablation therapy.

Learn about stage 2 vaginal cancer, including symptoms, diagnosis, treatment options, side effects and questions to discuss with your care team.

A real-world study found TKIs were the most common therapy for adults with metastatic renal cell carcinoma after prior immune checkpoint inhibitor use.

The FDA approved Poherdy as the first interchangeable biosimilar to Perjeta for patients with HER2-positive breast cancer.

The FDA has granted orphan drug designation to tinostamustine, an investigational therapeutic, for the treatment of patients with malignant gliomas.

Leading oncology experts share emerging research and developments shaping the year ahead, from precision medicine to innovative cancer therapies.

Dr. Suneel Kamath sat down for Pancreatic Cancer Awareness Month to discuss advances in treatment and the importance of raising awareness for this disease.

For some with GIST, bezuclastinib plus Sutent led to longer progression-free survival and higher response rates compared with Sutent alone.

In recognition of Pancreatic Cancer Awareness Month, Dr. Suneel Kamath sat down for an interview where he shared his insights on this aggressive disease.

This guide provides an overview of stage 2 uterine (endometrial) cancer, including diagnosis, treatment options, and common side effects. A cancer diagnosis is life-changing, and it is natural to feel

October brought developments in the management of blood cancers, from early-stage multiple myeloma to new cellular therapies and novel drug designations.

In the ASCENT-07 trial, Trodelvy after endocrine therapy did not improve progression-free survival vs chemotherapy in HR+/HER2- metastatic breast cancer.

October brought updates in the lung cancer field, ranging from notable trial results to patient perspectives on navigating treatment and survivorship.

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape genitourinary cancer care.

This year’s Breast Cancer Awareness Month highlighted FDA approvals, survivorship challenges and advances in breast reconstruction.

This is an essential guide on stage 2 cervical cancer to support patients in discussing diagnosis, treatment, and care decisions with their oncology team.

In October 2025, the FDA granted approval to multiple new cancer therapies and supportive care options, covering treatments across the oncologic landscape.

Participating in the SUNRiSE-1 trial taught Bill, a USC Norris patient, the value of education, teamwork, and persistence for patients with bladder cancer.

An expert discusses why up to 60% of new trial sites close in year one and what this means for patient access and research supply.